Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
45 hedge funds and large institutions have $453M invested in Day One Biopharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 8 closing their positions.
150% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 8
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
36% more funds holding
Funds holding: 33 → 45 (+12)
13% more capital invested
Capital invested by funds: $401M → $453M (+$51.9M)
1.5% more ownership
Funds ownership: 29.33% → 30.83% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$21.4M |
| 2 |
BlackRock
New York
|
+$12.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.81M |
| 4 |
Millennium Management
New York
|
+$4.26M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$6.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.79M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.61M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$3.12M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$2.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$264K | -11,594 | Closed |
|
|
ECM
52
ExodusPoint Capital Management
New York
| – | -$213K | -9,372 | Closed |
|
|
MS
53
Maven Securities
St Helier,
Jersey
| – | -$210K | -9,000 | Closed |
|
DAWN Hedge Fund Activity: Q3 2021 in Review
45 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2021, worth a combined $453M — up 13% from $401M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DAWN positions and 8 closed out — a net gain of 12 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Deerfield Management, adding an estimated $21.4M. The largest seller was Janus Henderson Group, cutting an estimated $6.6M.
- 45 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2021, up from 33 in Q2 2021.
- Funds reported $453M of Day One Biopharmaceuticals stock for Q3 2021, up 13% quarter-over-quarter.
- 20 funds opened new Day One Biopharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +12 holders.
- The largest Day One Biopharmaceuticals buyer in Q3 2021 was Deerfield Management, an estimated $21.4M added.
- The largest Day One Biopharmaceuticals seller in Q3 2021 was Janus Henderson Group, an estimated $6.6M sold.
Based on aggregated 13F filings for Q3 2021.